• Consensus Rating: Buy
  • Consensus Price Target: $32.67
  • Forecasted Upside: 90.14%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$17.18
▼ -0.2 (-1.15%)

This chart shows the closing price for IMNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunome Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMNM

Analyst Price Target is $32.67
▲ +90.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $32.67, with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 90.14% upside from the last price of $17.18.

This chart shows the closing price for IMNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Immunome. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024GuggenheimInitiated CoverageBuy$35.00Low
4/1/2024WedbushBoost TargetOutperform ➝ Outperform$27.00 ➝ $33.00Low
1/29/2024Leerink PartnrsReiterated RatingOutperformLow
1/29/2024SVB LeerinkInitiated CoverageOutperform$30.00Low
1/23/2024WedbushBoost TargetOutperform ➝ Outperform$12.00 ➝ $19.00Low
1/8/2024WedbushReiterated RatingOutperform$12.00Low
12/19/2023WedbushInitiated CoverageOutperform$12.00Low
7/10/2023Chardan CapitalReiterated RatingBuyLow
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
3/16/2023Chardan CapitalLower TargetBuy$9.00 ➝ $8.00Low
5/13/2022Chardan CapitalLower Target$16.00 ➝ $9.00High
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/30/2022Chardan CapitalLower Target$21.00 ➝ $16.00High
1/11/2022Cantor FitzgeraldLower Target$35.00 ➝ $33.00High
10/29/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Low
8/20/2021Chardan CapitalBoost TargetBuy$18.00 ➝ $21.00High
7/7/2021Chardan CapitalReiterated RatingBuyMedium
10/27/2020Chardan CapitalInitiated CoverageBuy$18.00High
10/26/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/21/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/20/2024
  • 8 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/19/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/20/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Immunome logo
Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $17.18
Low: $17.15
High: $17.97

50 Day Range

MA: $23.03
Low: $17.18
High: $27.34

52 Week Range

Now: $17.18
Low: $4.44
High: $30.96

Volume

852,654 shs

Average Volume

699,043 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunome?

The following Wall Street analysts have issued reports on Immunome in the last twelve months: Cantor Fitzgerald, Chardan Capital, Guggenheim, Leerink Partnrs, SVB Leerink LLC, and Wedbush.
View the latest analyst ratings for IMNM.

What is the current price target for Immunome?

3 Wall Street analysts have set twelve-month price targets for Immunome in the last year. Their average twelve-month price target is $32.67, suggesting a possible upside of 90.1%. Guggenheim has the highest price target set, predicting IMNM will reach $35.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $30.00 for Immunome in the next year.
View the latest price targets for IMNM.

What is the current consensus analyst rating for Immunome?

Immunome currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMNM will outperform the market and that investors should add to their positions of Immunome.
View the latest ratings for IMNM.

What other companies compete with Immunome?

How do I contact Immunome's investor relations team?

The company's listed phone number is 610-321-3700 and its investor relations email address is [email protected]. The official website for Immunome is immunome.com. Learn More about contacing Immunome investor relations.